dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade de São Paulo (USP)
dc.date.accessioned2015-08-21T17:53:27Z
dc.date.available2015-08-21T17:53:27Z
dc.date.created2015-08-21T17:53:27Z
dc.date.issued2014
dc.identifierPlatelets, v. 26, n. 2, p. 101-113, 2014.
dc.identifier1369-1635
dc.identifierhttp://hdl.handle.net/11449/126912
dc.identifier10.3109/09537104.2014.881991
dc.identifier1126105849856055
dc.identifier2620573504503756
dc.description.abstractThe clinical use of platelet-rich plasma (PRP) is based on the increase in the concentration of growth factors and in the secretion of proteins which are able to maximize the healing process at the cellular level. Since PRP is an autologous biologic material, it involves a minimum risk of immune reactions and transmission of infectious and contagious diseases, and it has been widely used for the recovery of musculoskeletal lesions. Despite the great potential for applicability, the implementation of the therapeutic employment of PRP as a clinical alternative has become difficult, due to the lack of studies related to the standardization of the techniques and/or insufficient description of the adopted procedures. Therefore, it is required establish standard criteria to be followed for obtaining a PRP of high quality, as well as a larger number of studies which should establish the proper concentration of platelets for the different clinical conditions. In this context, the purpose of this review is to discuss some methodological aspects used for achieving the PRP, as well as to discuss the bioactive properties of PRP, and to point out its therapeutic use in different fields of regenerative medicine.
dc.languageeng
dc.relationPlatelets
dc.relation0,721
dc.rightsAcesso restrito
dc.sourceCurrículo Lattes
dc.subjectBone
dc.subjectCartilage
dc.subjectMuscle
dc.subjectPlatelet-rich
dc.subjectPlasma
dc.subjectTendon
dc.titlePlatelet-rich plasma (PRP): methodological aspects and clinical applications
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución